Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
International Study of Improving Treatment for the Most Severely Ill With Schizophrenia
NCT00272584Phase 4Completed
- Sponsor
- University of British Columbia
- Start
- Jun 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in schizophrenia comparing Risperidone Augmentation with Placebo Augmentation (2 arms). Primary endpoint: Positive and Negative Syndrome Scale Total Score at 9 weeks. Started Jun 2001; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00272584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00272584.